|1.||Monia, Brett P: 29 articles (05/2015 - 03/2002)|
|2.||Guinan, Patrick: 23 articles (09/2014 - 01/2003)|
|3.||Rubenstein, Marvin: 23 articles (09/2014 - 01/2003)|
|4.||Hollowell, Courtney M P: 13 articles (09/2014 - 12/2010)|
|5.||Bhanot, Sanjay: 11 articles (05/2015 - 06/2005)|
|6.||Aartsma-Rus, Annemieke: 11 articles (01/2015 - 08/2004)|
|7.||Bennett, C Frank: 10 articles (11/2015 - 08/2006)|
|8.||Hung, Gene: 10 articles (11/2015 - 08/2006)|
|9.||Gleave, Martin: 10 articles (04/2015 - 01/2002)|
|10.||Ljubimova, Julia Y: 10 articles (01/2014 - 10/2003)|
12/01/1999 - "In the aspect of potential therapeutic approaches, some pharmaceutical drugs or antisense oligonucleotides that repress Evi-1 expression would be useful for the treatment of Evi-1-induced neoplastic tumors."
02/01/2013 - "The use of endogenous inhibitors of bcl-xL and other anti-apoptotic genes such as hsa-miR-15a-3p may provide improved options for apoptosis-modulating therapies in cancer treatment compared with the use of artificial antisense oligonucleotides."
01/01/2016 - "In this study, using splice-switching antisense oligonucleotides (ASOs), we increased the synthesis of Mcl-1S, which induced a concurrent reduction of Mcl-1L, resulting in increased sensitivity of cancer cells to apoptotic stimuli. "
10/01/2012 - "Indeed, known nucleotide sequences of cancer-relevant genes offer the possibility to rapidly design antisense oligonucleotides (ASO) for loss-of-function and preclinical proof-of-principle studies and subsequent clinical use. "
08/01/2010 - "Consequently, they represent prime candidates for anti-cancer therapy and specific antisense oligonucleotides or small molecule inhibitors have shown broad anti-cancer activities in pre-clinical models and are currently tested in clinical trials. "
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2013 - "Antisense oligonucleotides (oligos) have been employed against prostate cancer models in both in vivo and in vitro systems. "
01/01/2013 - "Antisense oligonucleotides (ASONs) were used to interfere the expression of Bfl-1 and its effects on prostate cancer cells. "
06/01/2012 - "Antisense oligonucleotides (oligos) have been administered against in vivo and in vitro prostate cancer models employing LNCaP and PC-3 cell lines. "
12/01/2011 - "Antisense oligonucleotides (oligos) have been employed against in vivo and in vitro prostate cancer models targeting growth stimulatory gene products. "
09/01/2011 - "Antisense oligonucleotides (oligos) have been evaluated in both in vivo and in vitro prostate cancer models. "
01/01/2012 - "Therefore, we hypothesized that, after the development of diet-induced obesity (DIO), metabolic function could be improved by administration of HIF-1α antisense oligonucleotides (ASO). "
08/01/2014 - "We then intraperitoneally injected morpholino antisense oligonucleotides (MO-mxd3) to knockdown mxd3 gene expression in DIO-zebrafish and measured several parameters, which reflected human obesity and associated metabolic diseases. "
08/01/2003 - "Inhibiting PTP1B action using antisense oligonucleotides and small molecule inhibitors represents novel therapeutic approach for the treatment of insulin resistance, type II diabetes, and obesity. "
05/01/2015 - "Since lowering TTR levels increases renal clearance of RBP4, we determined whether decreasing TTR levels with antisense oligonucleotides (ASOs) improves glucose metabolism and insulin sensitivity in obesity. "
06/06/2012 - "Insulin signaling becomes more important in the pathological context of obesity, as knockdown of the insulin receptor in ob/ob mice, a model of Type 2 diabetes, using antisense oligonucleotides, abolishes the induction of SREBP-1c and its targets by obesity and ameliorates steatosis. "
12/01/2010 - "To study the impacts of RelA antisense oligonucleotides on proliferation in laryngeal carcinoma Hep-2 cell. "
01/01/2015 - "Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells."
01/01/2011 - "Antisense oligonucleotides of WT1 may potentially help with the gene therapy of ovarian carcinoma."
12/01/2010 - "RelA antisense oligonucleotides was designed, which was transferred into laryngeal carcinoma Hep-2 cell. "
12/01/2010 - "[Impact of RelA antisense oligonucleotides on laryngeal carcinoma Hep-2 cell proliferation]."
|5.||Body Weight (Weight, Body)
11/01/2015 - "A single intracerebroventricular administration of the antisense oligonucleotides in the presymptomatic phase efficiently suppressed the mutant gene expression in the CNS, and delayed the onset and progression of motor dysfunction, improved body weight gain and survival with the amelioration of neuronal histopathology in motor units such as spinal motor neurons, neuromuscular junctions and skeletal muscle. "
01/01/2013 - "Treatment of diet-induce obese (DIO) mice with FGFR4 antisense oligonucleotides (ASO) specifically reduced liver FGFR4 expression that not only resulted in decrease in body weight (BW) and adiposity in free-feeding conditions, but also lowered BW and adiposity under caloric restriction. "
10/01/2000 - "The antisense oligonucleotides also significantly improved the loss of body weight, the increase in lung hydroxyproline, and histologic changes by BLM, whereas the antisense oligonucleotides themselves did not produce any significant changes in the behavior or lung histology. "
10/25/1994 - "Through PVN injection studies with antisense oligonucleotides to Gal mRNA, a dramatic decline in fat ingestion and body weight suggests that endogenous Gal contributes to the natural appetite for fat. "
10/01/2000 - "We examined the effect of antisense oligonucleotides to the p65 subunit of NF-kappaB on the survival of bleomycin (BLM)-induced pneumonitis in C57BL/6 mice (female, 8 wk of age, 17 to 20 g body weight). "
|1.||Messenger RNA (mRNA)
|2.||Transforming Growth Factor alpha (TGF-alpha)
|4.||Epidermal Growth Factor Receptor (EGF Receptor)
|5.||polylactic acid-polyglycolic acid copolymer (PLGA)
|6.||Proteins (Proteins, Gene)
|7.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|9.||Catalytic DNA (Deoxyribozyme)
|10.||Small Interfering RNA (siRNA)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)